# A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).

> **NCT05858749** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 494 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05858749
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-20
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 494 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05858749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05858749, "A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT05858749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*